Windtree Delisted from Nasdaq as BNB Hits Record High
Windtree Therapeutics was delisted from Nasdaq on August 21, 2025, after its aggressive BNB treasury strategy failed to lift its share price above the $1 minimum. The biotech’s planned purchase of up to $200 million in Binance Coin (BNB) briefly boosted the stock, but shares plunged 77% and never met listing requirements. Trading will move to over-the-counter markets under ticker “WINT,” where liquidity and bid-ask spreads may worsen. Meanwhile, BNB hit an all-time high amid strong market momentum and institutional inflows, highlighting a divergence between corporate crypto bets and token performance. Traders should monitor liquidity conditions, official filings and compliance updates to gauge market risks.
Bullish
BNB’s price surge to a record high, despite Windtree’s delisting, indicates strong market demand and institutional interest. Short-term, the token’s momentum and inflows create bullish pressure as traders chase gains and liquidity in OTC markets remains ample. Long-term, the divergence between corporate crypto bets and token performance underscores BNB’s resilience and potential to decouple from individual company outcomes. While Windtree’s failure to support its share price highlights risks of aggressive treasury strategies, it has little direct impact on BNB’s fundamentals, reinforcing a bullish outlook.